The relationship between the expression of Ki-67 and the prognosis of osteosarcoma

BackgroundA number of studies have linked positive Ki-67 expression with the prognosis of osteosarcoma (OS) patients. However, the results have been conflicting. To address this controversy, we conducted an analysis using a meta-analysis and a TCGA dataset to estimate the value of Ki-67 expression in the prognosis of OS.MethodsA comprehensive search for relevant papers was conducted using NCBI PubMed, Embase, Springer, ISI Web of Knowledge, the Cochrane Library, and CNKI regardless of the publication year. The associations between Ki-67 expression and the clinical features and main prognostic outcomes of OS were measured. The TCGA dataset was also analyzed. The pooled odds ratio (OR) and its 95% confidential intervals (CIs) were utilized for statistical analysis.ResultsOverall, a total of 12 studies with 500 cases were included, and the results indicated that the expression of Ki-67 was significantly associated with Enneking stage (OR=6.88, 95% CI: 2.92-16.22, p<0.05), distant metastasis (OR=3.04, 95% CI: 1.51-6.12, p<0.05) and overall survival (OR=8.82, 95% CI: 4.68-16.65, p<0.05) in OS patients. Additionally, we observed no significant heterogeneity among all retrieved studies. Associations between Ki-67 expression and overall survival and disease-free survival of sarcoma were confirmed using the TCGA and Kaplan-Meier plotter datasets.ConclusionThe present study strongly suggests that positive Ki-67 expression was associated with Enneking stage, distant metastasis, and overall survival of OS, and it may be used as a potential biomarker to predict prognosis and guide clinical therapy for OS.

Automated summary

Positive Ki-67 expression is significantly associated with Enneking stage, distant metastasis, and overall survival of osteosarcoma patients, suggesting it may serve as a potential biomarker for predicting prognosis and guiding clinical therapy.